RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis

S Ponce Aix,S Novello,EB Garon,K Nakagawa,E Nadal,D Moro-Sibilot,M Alonso Garcia,E Fabre,B Frimodt-Moller,AH Zimmermann,CM Visseren-Grul,M Reck

Cancer treatment and research communications（2021）

引用 12|浏览2

暂无评分

摘要

•Ramucirumab+erlotinib showed superior PFS over placebo+erlotinib in the RELAY trial.•Activating EGFR mutations are less prevalent in Western populations.•Ramucirumab+erlotinib provided similar benefit in Western and overall populations.•Results are applicable per the proposed indication, regardless of patient origin.

查看译文

关键词

Ethnicity,Epidermal growth factor receptor,Phase III,Regional subset,Vascular endothelial growth factor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要